ICER finds bluebird's potential $2.1M gene therapy cost-effective as FDA adcomm scheduled for June
The cost-effectiveness watchdog ICER said Wednesday that bluebird’s potential gene therapy for a rare blood disorder — which goes before an FDA adcomm in June — could be cost-effective even though it may be one of the most expensive drugs to ever hit the US market.
At the proposed price of $2.1 million per treatment course (to be paid across five years, given treatment success), ICER said that all eligible patients could be treated with Zynteglo, or beti-cel, which is already approved in the EU, over that span without crossing the watchdog’s budget impact threshold of $734 million per year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
